华夏英泰 email format

Founded in March 2018, China Immunotech (Beijing) Biotechnology Co. Ltd. is dedicated to biopharmaceutical research and development. We focus on developing and commercializing the products of cellular immunotherapy for cancer and other diseases. The STAR-T and TCR-T are the two unique core technological platforms developed by our company. Our founder and leading scientist, Dr. Xin Lin, is an immunologist and professor at Tsinghua University in Beijing, China. Our company is a successful model of the translation of scientific and technological achievements at Tsinghua University. Based on the unique core technologies, mature developing techniques, quality controlled industrial platforms, and wide range clinical cooperation, our company has filed and launched seven "first in human" clinical studies. We have already successfully treated more than 20 patients using our TCR-T/STAR-T/CAR-T cell transfusion therapy. The clinical study data provided very positive evidences about safety and effectiveness of the treatments. Some projects are in the process of applying for new drug IND. With distinctive features of remarkable R&D advantages, technology driven innovation, unique dual technology platforms, numerous pipelines and excellent expansibility, we are pursuing a strong and fast industrializing goal, and building a technology based, highly effective, translational medicine developing company. By innovating science and fighting cancer, our mission at China Immunotech is to prospect the future together with you.